

Mariagrazia Pizza

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6128134/publications.pdf>

Version: 2024-02-01

153
papers

10,959
citations

28274

55
h-index

31849

101
g-index

163
all docs

163
docs citations

163
times ranked

7534
citing authors

#	ARTICLE	IF	CITATIONS
1	Evolution of strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in France. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5614-5622.	3.3	5
2	Animal models in vaccinology: state of the art and future perspectives for an animal-free approach. <i>Current Opinion in Microbiology</i> , 2022, 66, 46-55.	5.1	1
3	The trillion dollar vaccine gap. <i>Science Translational Medicine</i> , 2022, 14, eabn4342.	12.4	14
4	Synergistic activity of antibodies in the multicomponent 4CMenB vaccine. <i>Expert Review of Vaccines</i> , 2022, 21, 645-658.	4.4	9
5	Structural characterization of a cross-protective natural chimera of factor H binding protein from meningococcal serogroup B strain NLO96. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 2070-2081.	4.1	0
6	Development and Characterisation of a Four-Plex Assay to Measure <i>Streptococcus pyogenes</i> Antigen-Specific IgG in Human Sera. <i>Methods and Protocols</i> , 2022, 5, 55.	2.0	6
7	4CMenB Immunization Induces Serum Bactericidal Antibodies Against Non-Serogroup B Meningococcal Strains in Adolescents. <i>Infectious Diseases and Therapy</i> , 2021, 10, 307-316.	4.0	17
8	Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2225-2231.	3.3	5
9	Vaccinology in the post-COVID-19 era. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	62
10	High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007-2011: Concordant predictions between MATS and genetic MATS. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 3230-3238.	3.3	7
11	Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination. <i>Journal of Infection</i> , 2021, 83, 17-26.	3.3	26
12	Looking beyond meningococcal B with the 4CMenB vaccine: the <i>Neisseria</i> effect. <i>Npj Vaccines</i> , 2021, 6, 130.	6.0	24
13	Four-component Meningococcal Serogroup B Vaccine Induces Antibodies With Bactericidal Activity Against Diverse Outbreak Strains in Adolescents. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, e66-e71.	2.0	7
14	Vaccines 2020: The era of the digital vaccine is here. <i>Science Translational Medicine</i> , 2021, 13, eabm3249.	12.4	13
15	Vaccines to Overcome Antibiotic Resistance: The Challenge of <i>Burkholderia cenocepacia</i> . <i>Trends in Microbiology</i> , 2020, 28, 315-326.	7.7	21
16	Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 945-948.	3.3	7
17	Vaccines against Meningococcal Diseases. <i>Microorganisms</i> , 2020, 8, 1521.	3.6	82
18	Methods to evaluate serogroup B meningococcal vaccines: From predictions to real-world evidence. <i>Journal of Infection</i> , 2020, 81, 862-872.	3.3	25

#	ARTICLE	IF	CITATIONS
19	Genomic Characterization of Invasive Meningococcal Serogroup B Isolates and Estimation of 4CMenB Vaccine Coverage in Finland. <i>MSphere</i> , 2020, 5, .	2.9	5
20	Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. <i>Vaccine</i> , 2020, 38, 7542-7550.	3.8	25
21	Vaccines Against Antimicrobial Resistance. <i>Frontiers in Immunology</i> , 2020, 11, 1048.	4.8	76
22	Molecular determinants of surface colonisation in diarrhoeagenic <i>Escherichia coli</i> (DEC): from bacterial adhesion to biofilm formation. <i>FEMS Microbiology Reviews</i> , 2020, 44, 314-350.	8.6	34
23	Meningococcal factor H binding protein as immune evasion factor and vaccine antigen. <i>FEBS Letters</i> , 2020, 594, 2657-2669.	2.8	14
24	4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp. <i>PLoS Pathogens</i> , 2020, 16, e1008882.	4.7	6
25	Vaccinology – Editorial. <i>Seminars in Immunology</i> , 2020, 50, 101439.	5.6	1
26	NHBA is processed by kallikrein from human saliva. <i>PLoS ONE</i> , 2019, 14, e0203234.	2.5	8
27	The meningococcal vaccine antigen GNA2091 is an analogue of YraP and plays key roles in outer membrane stability and virulence. <i>FASEB Journal</i> , 2019, 33, 12324-12335.	0.5	6
28	The Development of a Vaccine Against Meningococcus B Using Reverse Vaccinology. <i>Frontiers in Immunology</i> , 2019, 10, 751.	4.8	94
29	Identification of lipid A deacylase as a novel, highly conserved and protective antigen against enterohemorrhagic <i>Escherichia coli</i> . <i>Scientific Reports</i> , 2019, 9, 17014.	3.3	4
30	Mixed mucosal-parenteral immunizations with the broadly conserved pathogenic <i>Escherichia coli</i> antigen SslE induce a robust mucosal and systemic immunity without affecting the murine intestinal microbiota. <i>Vaccine</i> , 2019, 37, 314-324.	3.8	11
31	Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 725-731.	3.3	12
32	Crystal structure reveals vaccine elicited bactericidal human antibody targeting a conserved epitope on meningococcal fHbp. <i>Nature Communications</i> , 2018, 9, 528.	12.8	18
33	A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (Tdap) booster vaccines in adults. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 45-58.	3.3	8
34	Meningococcal B vaccine (4CMenB): the journey from research to real world experience. <i>Expert Review of Vaccines</i> , 2018, 17, 1111-1121.	4.4	60
35	NadA3 Structures Reveal Undecad Coiled Coils and LOX1 Binding Regions Competed by Meningococcus B Vaccine-Elicited Human Antibodies. <i>MBio</i> , 2018, 9, .	4.1	19
36	Vaccines Against <i>Escherichia coli</i> . <i>Current Topics in Microbiology and Immunology</i> , 2018, 416, 213-242.	1.1	24

#	ARTICLE	IF	CITATIONS
37	Intestinal Pathogenic Escherichia coli: Insights for Vaccine Development. <i>Frontiers in Microbiology</i> , 2018, 9, 440.	3.5	71
38	Outer Membrane Vesicles (OMV)-based and Proteomics-driven Antigen Selection Identifies Novel Factors Contributing to <i>Bordetella pertussis</i> Adhesion to Epithelial Cells. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 205-215.	3.8	38
39	Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007-08 and 2014-15: a qualitative and quantitative assessment. <i>Lancet Infectious Diseases</i> , The. 2017, 17, 754-762.	9.1	60
40	Emerging experience with meningococcal serogroup B protein vaccines. <i>Expert Review of Vaccines</i> , 2017, 16, 433-451.	4.4	54
41	Potential impact of the 4CMenB vaccine on oropharyngeal carriage of <i>Neisseria meningitidis</i> . <i>Journal of Infection</i> , 2017, 75, 511-520.	3.3	4
42	Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse model. <i>Vaccine</i> , 2017, 35, 5256-5263.	3.8	46
43	Recombinant BCG Expressing LTAK63 Adjuvant induces Superior Protection against <i>Mycobacterium tuberculosis</i> . <i>Scientific Reports</i> , 2017, 7, 2109.	3.3	16
44	Spotlight on Mariagrazia Pizza. <i>FEMS Microbiology Letters</i> , 2017, 364, fnw299.	1.8	1
45	Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Portugal. <i>PLoS ONE</i> , 2017, 12, e0176177.	2.5	17
46	Identification of the Autochaperone Domain in the Type Va Secretion System (T5aSS): Prevalent Feature of Autotransporters with a β^2 -Helical Passenger. <i>Frontiers in Microbiology</i> , 2017, 8, 2607.	3.5	17
47	Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent <i>Neisseria meningitidis</i> W Strain, England. <i>Emerging Infectious Diseases</i> , 2016, 22, 309-311.	4.3	89
48	<i>Neisserial</i> Heparin Binding Antigen (NHBA) Contributes to the Adhesion of <i>Neisseria meningitidis</i> to Human Epithelial Cells. <i>PLoS ONE</i> , 2016, 11, e0162878.	2.5	33
49	Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 2714-2719.	7.1	73
50	Exploring host-pathogen interactions through genome wide protein microarray analysis. <i>Scientific Reports</i> , 2016, 6, 27996.	3.3	24
51	A novel high-throughput assay to quantify the vaccine-induced inhibition of <i>Bordetella pertussis</i> adhesion to airway epithelia. <i>BMC Microbiology</i> , 2016, 16, 215.	3.3	10
52	Exploiting chimeric human antibodies to characterize a protective epitope of <i>Neisseria</i> adhesin A, one of the Bexsero vaccine components. <i>FASEB Journal</i> , 2016, 30, 93-101.	0.5	10
53	Molecular Basis of Ligand-Dependent Regulation of NadR, the Transcriptional Repressor of Meningococcal Virulence Factor NadA. <i>PLoS Pathogens</i> , 2016, 12, e1005557.	4.7	24
54	LytM Proteins Play a Crucial Role in Cell Separation, Outer Membrane Composition, and Pathogenesis in Nontypeable <i>Haemophilus influenzae</i> . <i>MBio</i> , 2015, 6, e02575.	4.1	42

#	ARTICLE	IF	CITATIONS
55	Pathogenic <i>E. coli</i> Exploits SslE Mucinase Activity to Translocate through the Mucosal Barrier and Get Access to Host Cells. <i>PLoS ONE</i> , 2015, 10, e0117486.	2.5	55
56	Development of a serological assay to predict antibody bactericidal activity against non-typeable <i>Haemophilus influenzae</i> . <i>BMC Microbiology</i> , 2015, 15, 87.	3.3	11
57	Dual RNA-seq of Nontypeable <i>Haemophilus influenzae</i> and Host Cell Transcriptomes Reveals Novel Insights into Host-Pathogen Cross Talk. <i>MBio</i> , 2015, 6, e01765-15.	4.1	123
58	Whole-Genome Sequences of Nonencapsulated <i>Haemophilus influenzae</i> Strains Isolated in Italy. <i>Genome Announcements</i> , 2015, 3, .	0.8	3
59	The potential of adjuvants to improve immune responses against Tdap vaccines: A preclinical evaluation of MF59 and monophosphoryl lipid A. <i>International Journal of Pharmaceutics</i> , 2015, 492, 169-176.	5.2	15
60	<i>Neisseria meningitidis</i> subverts the polarized organization and intracellular trafficking of host cells to cross the epithelial barrier. <i>Cellular Microbiology</i> , 2015, 17, 1365-1375.	2.1	20
61	Molecular Engineering of Ghfp, the Gonococcal Orthologue of <i>Neisseria meningitidis</i> Factor H Binding Protein. <i>Vaccine Journal</i> , 2015, 22, 769-777.	3.1	8
62	<i>Neisseria meningitidis</i> : pathogenesis and immunity. <i>Current Opinion in Microbiology</i> , 2015, 23, 68-72.	5.1	104
63	Recognition of <i>Neisseria meningitidis</i> by the Long Pentraxin PTX3 and Its Role as an Endogenous Adjuvant. <i>PLoS ONE</i> , 2015, 10, e0120807.	2.5	29
64	The <i>Neisseria meningitidis</i> ADP-Ribosyltransferase NarE Enters Human Epithelial Cells and Disrupts Epithelial Monolayer Integrity. <i>PLoS ONE</i> , 2015, 10, e0127614.	2.5	4
65	Role of ARF6, Rab11 and External Hsp90 in the Trafficking and Recycling of Recombinant-Soluble <i>Neisseria meningitidis</i> Adhesin A (rNadA) in Human Epithelial Cells. <i>PLoS ONE</i> , 2014, 9, e110047.	2.5	16
66	<i>Neisseria</i> Adhesin A Variation and Revised Nomenclature Scheme. <i>Vaccine Journal</i> , 2014, 21, 966-971.	3.1	54
67	Two cross-reactive monoclonal antibodies recognize overlapping epitopes on <i>Neisseria meningitidis</i> factor H binding protein but have different functional properties. <i>FASEB Journal</i> , 2014, 28, 1644-1653.	0.5	34
68	SslE Elicits Functional Antibodies That Impair In Vitro Mucinase Activity and In Vivo Colonization by Both Intestinal and Extraintestinal <i>Escherichia coli</i> Strains. <i>PLoS Pathogens</i> , 2014, 10, e1004124.	4.7	54
69	Genetically detoxified pertussis toxin (PT-9K/129G): implications for immunization and vaccines. <i>Expert Review of Vaccines</i> , 2014, 13, 1191-1204.	4.4	36
70	Vaccines, new opportunities for a new society. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 12288-12293.	7.1	237
71	Structure of the meningococcal vaccine antigen NadA and epitope mapping of a bactericidal antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 17128-17133.	7.1	60
72	Variability of genes encoding surface proteins used as vaccine antigens in meningococcal endemic and epidemic strain panels from Norway. <i>Vaccine</i> , 2014, 32, 2722-2731.	3.8	9

#	ARTICLE	IF	CITATIONS
73	Genome sequencing of disease and carriage isolates of nontypeable <i>Haemophilus influenzae</i> identifies discrete population structure. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 5439-5444.	7.1	104
74	The C2 fragment from <i>Neisseria meningitidis</i> antigen NHBA increases endothelial permeability by destabilizing adherens junctions. Cellular Microbiology, 2014, 16, 925-937.	2.1	21
75	Molecular and Serological Diversity of <i>Neisseria meningitidis</i> Carrier Strains Isolated from Italian Students Aged 14 to 22 Years. Journal of Clinical Microbiology, 2014, 52, 1901-1910.	3.9	40
76	Protective Efficacy Induced by Recombinant <i>Clostridium difficile</i> Toxin Fragments. Infection and Immunity, 2013, 81, 2851-2860.	2.2	38
77	Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control <i>Neisseria meningitidis</i> capsular group X outbreaks in Africa?. Vaccine, 2013, 31, 1113-1116.	3.8	93
78	Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine, 2013, 31, 4968-4974.	3.8	123
79	Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infectious Diseases, The, 2013, 13, 416-425.	9.1	261
80	<i>Neisseria gonorrhoeae</i> PIII has a role on NG1873 outer membrane localization and is involved in bacterial adhesion to human cervical and urethral epithelial cells. BMC Microbiology, 2013, 13, 251.	3.3	7
81	Conservation of Meningococcal Antigens in the Genus <i>Neisseria</i> . MBio, 2013, 4, e00163-13.	4.1	50
82	EsiB, a Novel Pathogenic <i>Escherichia coli</i> Secretory Immunoglobulin A-Binding Protein Impairing Neutrophil Activation. MBio, 2013, 4, .	4.1	22
83	Defining a protective epitope on factor H binding protein, a key meningococcal virulence factor and vaccine antigen. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3304-3309.	7.1	125
84	Transcriptional Regulation of the <i>nadA</i> Gene in <i>Neisseria meningitidis</i> Impacts the Prediction of Coverage of a Multicomponent Meningococcal Serogroup B Vaccine. Infection and Immunity, 2013, 81, 560-569.	2.2	52
85	Optimized fluorescent labeling to identify memory B cells specific for <i>Neisseria meningitidis</i> serogroup B vaccine antigens ex vivo. Immunity, Inflammation and Disease, 2013, 1, 3-13.	2.7	5
86	Diversity of <i>cwp</i> loci in clinical isolates of <i>Clostridium difficile</i> . Journal of Medical Microbiology, 2013, 62, 1444-1452.	1.8	16
87	An Analysis of the Sequence Variability of Meningococcal fHbp, NadA and NHBA over a 50-Year Period in the Netherlands. PLoS ONE, 2013, 8, e65043.	2.5	47
88	Interlaboratory Standardization of the Sandwich Enzyme-Linked Immunosorbent Assay Designed for MATS, a Rapid, Reproducible Method for Estimating the Strain Coverage of Investigational Vaccines. Vaccine Journal, 2012, 19, 1609-1617.	3.1	59
89	FdeC, a Novel Broadly Conserved <i>Escherichia coli</i> Adhesin Eliciting Protection against Urinary Tract Infections. MBio, 2012, 3, .	4.1	93
90	MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine. Human Vaccines and Immunotherapeutics, 2012, 8, 486-490.	3.3	34

#	ARTICLE	IF	CITATIONS
91	RrgB321, a Fusion Protein of the Three Variants of the Pneumococcal Pilus Backbone RrgB, Is Protective In Vivo and Elicits Opsonic Antibodies. <i>Infection and Immunity</i> , 2012, 80, 451-460.	2.2	39
92	Toward a Meningitis-Free World. <i>Science Translational Medicine</i> , 2012, 4, 123ps5.	12.4	22
93	Advances in meningococcal vaccines. <i>Clinical Practice (London, England)</i> , 2012, 9, 101-117.	0.1	4
94	Preface. <i>Vaccine</i> , 2012, 30, B1-B2.	3.8	1
95	Antigen Identification Starting from the Genome: A "Reverse Vaccinology" Approach Applied to MenB. <i>Methods in Molecular Biology</i> , 2012, 799, 361-403.	0.9	22
96	The Factor H Binding Protein of <i>Neisseria meningitidis</i> Interacts with Xenosiderophores in Vitro. <i>Biochemistry</i> , 2012, 51, 9384-9393.	2.5	17
97	<i>Escherichia coli</i> : Great Diversity around a Common Core. <i>MBio</i> , 2012, 3, .	4.1	31
98	Novel meningococcal 4CMenB vaccine antigens " prevalence and polymorphisms of the encoding genes in <i>Neisseria gonorrhoeae</i> . <i>Apmis</i> , 2012, 120, 750-760.	2.0	31
99	Human heat shock protein (Hsp) 90 interferes with <i>Neisseria meningitidis</i> adhesin A (NadA)-mediated adhesion and invasion. <i>Cellular Microbiology</i> , 2012, 14, 368-385.	2.1	28
100	Design of New Vaccines in the Genomic and Post-genomic Era. , 2012, , 3-15.		1
101	Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1. <i>Vaccine</i> , 2011, 29, 1072-1081.	3.8	47
102	Prevalence and genetic diversity of candidate vaccine antigens among invasive <i>Neisseria meningitidis</i> isolates in the United States. <i>Vaccine</i> , 2011, 29, 4739-4744.	3.8	98
103	NMR resonance assignments of NarE, a putative ADP-ribosylating toxin from <i>Neisseria meningitidis</i> . <i>Biomolecular NMR Assignments</i> , 2011, 5, 35-38.	0.8	5
104	Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults. <i>Hum Vaccin</i> , 2011, 7, 781-791.	2.4	28
105	A life passion for vaccines. <i>Hum Vaccin</i> , 2011, 7, 808-810.	2.4	0
106	<i>Escherichia coli</i> Heat-Labile Enterotoxin Promotes Protective Th17 Responses against Infection by Driving Innate IL-1 and IL-23 Production. <i>Journal of Immunology</i> , 2011, 186, 5896-5906.	0.8	94
107	Rational Design of a Meningococcal Antigen Inducing Broad Protective Immunity. <i>Science Translational Medicine</i> , 2011, 3, 91ra62.	12.4	135
108	<i>Neisseria meningitidis</i> is structured in clades associated with restriction modification systems that modulate homologous recombination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 4494-4499.	7.1	198

#	ARTICLE	IF	CITATIONS
109	Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 11169-11174.	7.1	149
110	Structural and Biochemical Characterization of NarE, an Iron-containing ADP-ribosyltransferase from <i>Neisseria meningitidis</i> . Journal of Biological Chemistry, 2011, 286, 14842-14851.	3.4	16
111	Structure of the C-terminal Domain of <i>Neisseria</i> Heparin Binding Antigen (NHBA), One of the Main Antigens of a Novel Vaccine against <i>Neisseria meningitidis</i> . Journal of Biological Chemistry, 2011, 286, 41767-41775.	3.4	33
112	A Naturally Occurring Single-Residue Mutation in the Translocator Domain of <i>Neisseria meningitidis</i> NhhA Affects Trimerization, Surface Localization, and Adhesive Capabilities. Infection and Immunity, 2011, 79, 4308-4321.	2.2	9
113	Transcriptome Analysis of <i>Neisseria meningitidis</i> in Human Whole Blood and Mutagenesis Studies Identify Virulence Factors Involved in Blood Survival. PLoS Pathogens, 2011, 7, e1002027.	4.7	129
114	Characterization of Diverse Subvariants of the Meningococcal Factor H (fH) Binding Protein for Their Ability To Bind fH, To Mediate Serum Resistance, and To Induce Bactericidal Antibodies. Infection and Immunity, 2011, 79, 970-981.	2.2	64
115	¹ H, ¹³ C and ¹⁵ N assignment of the C-terminal domain of GNA2132 from <i>Neisseria meningitidis</i> . Biomolecular NMR Assignments, 2010, 4, 107-109.	0.8	2
116	Characterization of fHbp, nhba (gna2132), nadA, porA, and Sequence Type in Group B Meningococcal Case Isolates Collected in England and Wales during January 2008 and Potential Coverage of an Investigational Group B Meningococcal Vaccine. Vaccine Journal, 2010, 17, 919-929.	3.1	95
117	<i>Neisseria meningitidis</i> GNA2132, a heparin-binding protein that induces protective immunity in humans. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3770-3775.	7.1	184
118	The Two Variants of the <i>Streptococcus pneumoniae</i> Pilus 1 RrgA Adhesin Retain the Same Function and Elicit Cross-Protection In Vivo. Infection and Immunity, 2010, 78, 5033-5042.	2.2	42
119	Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic <i>Escherichia coli</i> . Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 9072-9077.	7.1	222
120	Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 19490-19495.	7.1	267
121	Influence of serogroup B meningococcal vaccine antigens on growth and survival of the meningococcus in vitro and in ex vivo and in vivo models of infection. Vaccine, 2010, 28, 2416-2427.	3.8	33
122	Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine, 2010, 28, 5023-5030.	3.8	79
123	SR-A, MARCO and TLRs Differentially Recognise Selected Surface Proteins from <i>Neisseria meningitidis</i> : an Example of Fine Specificity in Microbial Ligand Recognition by Innate Immune Receptors. Journal of Innate Immunity, 2009, 1, 153-163.	3.8	38
124	Solution Structure of the Factor H-binding Protein, a Survival Factor and Protective Antigen of <i>Neisseria meningitidis</i> . Journal of Biological Chemistry, 2009, 284, 9022-9026.	3.4	55
125	Characterization of fHbp, nhba (gna2132), nadA, porA, Sequence Type (ST), and Genomic Presence of IS 1301 in Group B Meningococcal ST269 Clonal Complex Isolates from England and Wales. Journal of Clinical Microbiology, 2009, 47, 3577-3585.	3.9	71
126	HadA is an atypical new multifunctional trimeric coiled-coil adhesin of <i>Haemophilus influenzae</i> group aegyptius, which promotes entry into host cells. Cellular Microbiology, 2009, 11, 1044-1063.	2.1	35

#	ARTICLE	IF	CITATIONS
127	Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. <i>Vaccine</i> , 2009, 27, 2794-2803.	3.8	111
128	Meningococcal protein antigens and vaccines. <i>Vaccine</i> , 2009, 27, B42-B50.	3.8	56
129	Epitope Mapping of a Bactericidal Monoclonal Antibody against the Factor H Binding Protein of <i>Neisseria meningitidis</i> . <i>Journal of Molecular Biology</i> , 2009, 386, 97-108.	4.2	44
130	Factor H-binding protein, a unique meningococcal vaccine antigen. <i>Vaccine</i> , 2008, 26, I46-I48.	3.8	22
131	The Adjuvants Aluminum Hydroxide and MF59 Induce Monocyte and Granulocyte Chemoattractants and Enhance Monocyte Differentiation toward Dendritic Cells. <i>Journal of Immunology</i> , 2008, 180, 5402-5412.	0.8	370
132	Proteomics Characterization of Outer Membrane Vesicles from the Extraintestinal Pathogenic <i>Escherichia coli</i> β -toR IHE3034 Mutant. <i>Molecular and Cellular Proteomics</i> , 2008, 7, 473-485.	3.8	115
133	Outer membrane vesicles from group B <i>Neisseria meningitidis</i> gna33 mutant: Proteomic and immunological comparison with detergent-derived outer membrane vesicles. <i>Proteomics</i> , 2006, 6, 1856-1866.	2.2	151
134	<i>Neisseria meningitidis</i> NhhA is a multifunctional trimeric autotransporter adhesin. <i>Molecular Microbiology</i> , 2006, 61, 631-644.	2.5	82
135	A universal vaccine for serogroup B meningococcus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 10834-10839.	7.1	657
136	Identification of <i>Neisseria meningitidis</i> Nonlipopolysaccharide Ligands for Class A Macrophage Scavenger Receptor by Using a Novel Assay. <i>Infection and Immunity</i> , 2006, 74, 5191-5199.	2.2	53
137	Ng-MIP, a surface-exposed lipoprotein of <i>Neisseria gonorrhoeae</i> , has a peptidyl-prolyl isomerase (PPIase) activity and is involved in persistence in macrophages. <i>Molecular Microbiology</i> , 2005, 58, 669-681.	2.5	107
138	The Region Comprising Amino Acids 100 to 255 of <i>Neisseria meningitidis</i> Lipoprotein GNA 1870 Elicits Bactericidal Antibodies. <i>Infection and Immunity</i> , 2005, 73, 1151-1160.	2.2	88
139	NadA Diversity and Carriage in <i>Neisseria meningitidis</i> . <i>Infection and Immunity</i> , 2004, 72, 4217-4223.	2.2	127
140	Putative Vaccine Antigens from <i>Neisseria meningitidis</i> Recognized by Serum Antibodies of Young Children Convalescing after Meningococcal Disease. <i>Journal of Infectious Diseases</i> , 2004, 190, 1488-1497.	4.0	72
141	<i>Neisseria meningitidis</i> NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. <i>Molecular Microbiology</i> , 2004, 55, 687-698.	2.5	206
142	<i>Neisseria meningitidis</i> App, a new adhesin with autocatalytic serine protease activity. <i>Molecular Microbiology</i> , 2003, 48, 323-334.	2.5	94
143	Mutants of the <i>Escherichia coli</i> heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. <i>Expert Review of Vaccines</i> , 2003, 2, 285-293.	4.4	103
144	Two years into reverse vaccinology. <i>Vaccine</i> , 2003, 21, 605-610.	3.8	109

#	ARTICLE	IF	CITATIONS
145	Vaccination against <i>Neisseria meningitidis</i> Using Three Variants of the Lipoprotein GNA1870. <i>Journal of Experimental Medicine</i> , 2003, 197, 789-799.	8.5	388
146	NadA, a Novel Vaccine Candidate of <i>Neisseria meningitidis</i> . <i>Journal of Experimental Medicine</i> , 2002, 195, 1445-1454.	8.5	337
147	Modulation of Innate and Acquired Immune Responses by <i>Escherichia coli</i> Heat-Labile Toxin: Distinct Pro- and Anti-Inflammatory Effects of the Nontoxic AB Complex and the Enzyme Activity. <i>Journal of Immunology</i> , 2000, 165, 5750-5759.	0.8	101
148	Complete Genome Sequence of <i>Neisseria meningitidis</i> Serogroup B Strain MC58. <i>Science</i> , 2000, 287, 1809-1815.	12.6	1,083
149	Structure and mucosal adjuvanticity of cholera and <i>Escherichia coli</i> heat-labile enterotoxins. <i>Trends in Immunology</i> , 1999, 20, 493-500.	7.5	270
150	Mutants of <i>Escherichia coli</i> Heat-Labile Toxin Act as Effective Mucosal Adjuvants for Nasal Delivery of an Acellular Pertussis Vaccine: Differential Effects of the Nontoxic AB Complex and Enzyme Activity on Th1 and Th2 Cells. <i>Infection and Immunity</i> , 1999, 67, 6270-6280.	2.2	88
151	Genetically Detoxified Mutants of Heat-Labile Toxin from <i>Escherichia coli</i> Are Able To Act as Oral Adjuvants. <i>Infection and Immunity</i> , 1999, 67, 4400-4406.	2.2	70
152	Mucosal Adjuvanticity and Immunogenicity of LTR72, a Novel Mutant of <i>Escherichia coli</i> Heat-labile Enterotoxin with Partial Knockout of ADP-ribosyltransferase Activity. <i>Journal of Experimental Medicine</i> , 1998, 187, 1123-1132.	8.5	270
153	Meningococcal Vaccines: A Technological Revolution. <i>Frontiers for Young Minds</i> , 0, 8, .	0.8	0